On November 2, 2021, Sensyne Health plc (AIM:SENS) announced the launch of a strategic review and commencement of a Formal Sale Process. Since then, J.P. Morgan Securities plc (J.P. Morgan Cazenove) and Peel Hunt LLP (joint financial advisers to the Company) have contacted a broad range of corporates and financial sponsors to solicit interest in an offer for the Company or strategic investment into the Company. In light of the amended financing terms, the Board has decided to end the Formal Sale Process with immediate effect and the ongoing discussions with the parties referred to in the announcement of April 8, 2022 have been terminated.